Table 1.

TM-β1 pretreatment enhances human CD45⁺ cell distribution into the spleens of Hu-PBL-SCID and NOD-SCID mice

Mice were left untreated or were injected intraperitoneally with 1 mg TM-β1 24 h before reconstitution with 5 × 10⁶ Hu-PBL. One group of NOD-SCID mice was pretreated with TM-β1 and irradiated with 3 Gy (). At indicated time points, the presence of human CD45⁺ cells was measured by FACS analysis. Values are expressed as mean percentage CD45⁺ human cells ± s.e.m. (absolute numbers of human cells ± s.e.m.).

*P < 0.05 versus SCID mice; **P < 0.05 versus SCID and NOD-SCID; ***P < 0.05 versus SCID, NOD-SCID and SCID-TM-β1 mice; ****P < 0.05 versus all other groups.